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Abstract 
Platelet (PLT) transfusion, which is the primary cell therapy for thrombocytopenia, has been a source of concern in 
recent years due to its limitations of donor-dependent supply and soaring costs. In vitro platelet generation on an 
industrial scale is a possible solution requiring exploration. The technology of platelet generation ex vivo has been 
widely studied across the world, though the mechanisms of physiological thrombopoiesis and platelet biology func-
tion in vivo still remain elusive today. Various culture systems have been studied, most of which proved quite inef-
ficient in generating functional platelets ex vivo, so there is still a long way to reach our ultimate goal of generating 
a fully functional platelet in vitro on an industrial scale. This review integrates the latest research into physiological 
platelet biogenesis and ex vivo-platelet/megakaryocyte (MK) generation protocols with a focus on the ability to gen-
erate PLT/MK in large quantities, summarizes current culture systems based on induced human pluripotent stem cells 
and adipose-derived stem cells, and discusses significant challenges that must be overcome for these approaches to 
be perfected.
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Background
In healthy adults, human platelets maintain a normal 
level of approximately (150–400)  ×  103/μl in blood, 
with a short life span of only 7–10 days (Lu et al. 2011). 
There is considerable evidence that platelets play an 
essential role in hemostasis and thrombosis (Linden 
and Jackson 2010), maintaining vascular integrity (Ho-
Tin-noé et  al. 2011), angiogenesis, innate immunity 
(Semple et al. 2011), inflammation, cancer biology (Gay 
and Felding-Habermann 2011), and wound healing, 
among others (Menter et al. 2014). Clinically, abnormal 
changes in platelet quality and/or quantity will occur in 
response to various life-threatening conditions, includ-
ing thrombocytopenia, thrombocythemia, idiopathic 
thrombocytopenic purpura, myelodysplastic syndromes 
(MDS), chemotherapy-induced thrombocytopenia, 
aplastic anemia, human immunodeficiency virus (HIV) 
infection, and major cardiac surgery (Thon and Italiano 
2010). To mitigate risks associated with these condi-
tions, platelet transfusion is most commonly used as a 
kind of cell therapy. However, platelet transfusions are 
limited by alloimmunization, availability, and expense. 
Transfusions are, at present, totally donor depend-
ent, which leads to a limited supply for clinical therapy 
and creates a constant shortage in transfusion supplies. 
Meanwhile, the steady increase in demand is challeng-
ing every blood station around the world. Fortunately, 
there are considerable studies providing abundant evi-
dence that functional platelets can be generated in vitro, 
which shows significant advantages over the donor-
dependent supply, though many aspects of the process 
are poorly understood. The technology to generate fully 
functional platelets in  vitro on an industrial scale for 
clinical platelet transfusion is needed urgently (Reems 
et al. 2010).
Physiological thrombopoiesis process
Hematopoiesis and the marrow microenvironment
We consider that the ideal culture system to manufacture 
platelets in vitro should be characterized by certain prin-
ciples, including easiest operating system, most abundant 
precursor cell source, shortest culture period, highest 
yield efficiency, and fully functional platelets (EASHF 
rule). To most closely mimic the in vivo process of mega-
karyocyte (MK)/platelet (PLT) development when devel-
oping in  vitro approaches to platelet generation, it is 
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necessary to briefly review the in vivo process primarily 
responsible for megakaryocyte development and platelet 
biogenesis.
Currently accepted theory is that platelets are formed 
and released into the bloodstream by precursor cells 
called megakaryocytes derived from pluripotent 
hematopoietic stem cells (HSCs) that reside within the 
bone marrow. For additional information regarding this 
topic please see review Yin and Li (2006). Bone marrow 
(BM) consists of a hematopoietic component and sur-
rounding tissue. Mesenchymal stem cells (MSCs) give 
rise to a variety of cell types, including myocytes, adi-
pocytes, fibroblasts, endothelial cells, and osteoblasts 
(Taichman 2005). There are at least two niches in the 
bone marrow having been identified for HSC hemat-
opoiesis, including the osteoblastic niche and the vas-
cular niche.
Schofield first advanced the concept of niches in 1978, 
describing the microenvironment where stem cells reside 
in bone cavity (Schofield 1977). The bone cavity is filled 
with soft BM and other components. The stem cell niche 
is composed of a variety of cells for the maintenance of 
stem cells and generates extrinsic factors that control 
stem cell number (Li and Xie 2005) and fate with regard 
to self-renewal versus differentiation (Fuchs et  al. 2004; 
Spradling et  al. 2001). In mammals, some hematopoi-
etic cells live next to the endosteal bone surface, which 
is lined mainly by osteoblasts, suggesting reciprocal com-
munication between the two cell types. Osteoblasts have 
been identified as responsible for generation of a variety 
of hematopoietic growth factors (Taichman et  al. 1996, 
2001). Some studies demonstrated that osteoblasts were 
key components of the HSC niche for supporting HSC 
growth (Zhang et al. 2003; Calvi et al. 2003; Visnjic et al. 
2004). Additionally, experiments on osteoblast deple-
tion and ablation of endothelial cells showed hematopoi-
etic failure (Avecilla et  al. 2003). Another study further 
demonstrated adhesion of HSCs to osteoblasts on the 
endosteal surface, an essential molecular mechanism 
for maintaining HSC in quiescence (Arai et  al. 2004). 
The vascular niche consists of hematopoietic cells and 
endothelial cells, similarly to the composition of the oste-
oblastic niche; the two niches are also closely related dur-
ing development. The vascular niche and the osteoblastic 
niche are both derived from hemangioblasts (Kopp et al. 
2005). Functionally, vascular endothelial cells maintain 
HSCs in vitro and are required for hematopoiesis in vivo 
(Li et al. 2004). Studies have suggested that the vascular 
niche is the site of HSC differentiation and mobilization 
(Avecilla et al. 2003; Kopp et al. 2005). Thus, it is plausi-
ble that the osteoblastic niche provides a quiescent envi-
ronment for HSC maintenance and the vascular niche 
offers an alternative niche for mobilized stem cells and 
promotes proliferation and further differentiation or 
maturation into the circulation system. There are numer-
ous publications indicating that HSC return to the BM, 
so-called homing. However, the underlying physiologi-
cal function of these events remains elusive (Wright et al. 
2001).
In summary, both the osteoblastic niche and the vas-
cular niche have a likely important role in HSC mobili-
zation, which consists of HSCs leaving the osteoblastic 
niche, mobilizing to the vascular niche, entering blood 
vessels, and circulating in the vascular system. Homing of 
stem cells is simply the reversal of this process (Lapidot 
et al. 2005).
Megakaryopoiesis
A significant proportion of studies result in the conclu-
sion that the global process of thrombopoiesis includes: 
megakaryocyte precursor development from stem cells 
and cell fate determination; endomitosis and the devel-
opment of polyploidy; internal membrane, tubular, 
cytoskeletal, and granule evolution directed by key tran-
scription factors and transcriptional programs; regulated 
apoptosis; and additional intricate and time-dependent 
events (Gordge 2005; Italiano et al. 2007).
The megakaryocyte is the central cell in thrombopoie-
sis. Megakaryocytes originate from HSCs like other 
terminally differentiated hematopoietic cells, such as 
erythrocytes and neutrophils (Ogawa 1993). Further, 
Najet Debili and his colleagues further prove that mega-
karyocytes and erythroid lineages arise from a common 
megakaryocyte-erythroid progenitor (MEP) derived 
from the common myeloid progenitor (Debili et al. 1996), 
yet the signals that regulate the final separation of these 
lineages are not well understood. Megakaryopoiesis is 
established first in the embryonic yolk sac, though stud-
ies have shown that platelets are not very important for 
fetus survival (Shivdasani et al. 1995). Broadly speaking, 
there may be four primarily sequential biological stages 
for thrombopoiesis and megakaryopoiesis. The self-
renewal of HSCs living in the BM osteoblastic niches 
is the first step. Subsequently, stem cells proliferate and 
differentiate to increase the number of MK progenitors. 
In the third step of maturation events, MK progenitors 
undergo a process known as endomitosis that the DNA 
continue to replicate, but cytokinesis and nuclear divi-
sion fails and, as a result, they require a DNA content of 
up to many times the normal complement of 46 chro-
mosomes (i.e., >2  N). However, a significant proportion 
of MKs containing two physically separated nuclei have 
been reported recently. The fourth and last stage is char-
acterized by platelet assembly and release (Pang et  al. 
2005; Reems et  al. 2010). Thus, it is easy to understand 
that more MKs make more platelets in this process. 
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To date, large quantities of transcription factors and 
cytokines involving megakaryopoiesis, including granu-
locyte macrophage colony-stimulating factor (GM-CSF), 
IL-3, IL-6, IL-11, IL-12 (Gordon and Hoffman 1992), 
IL-1α and leukemia inhibitory factor (LIF) (Gordon and 
Hoffman 1992; Vainchenker et al. 1995), et al. The most 
noteworthy is that thrombopoietin (TPO), which is syn-
thesized predominantly in the liver (Jelkmann 2001), 
has been identified as markedly stimulating megakary-
octye production by combining with the MPL receptors 
(Kaushansky et al. 1994; Lok et al. 1994). In the end, the 
senescent MK nucleus remaining after platelet release is, 
predictably, disposed of by apoptosis and phagocytosis 
(Gordge 2005).
Proplatelet generation and platelet release
Platelet production is recognized as the final stage of 
megakaryoctye development so far. Mature megakaty-
octyes have the ability to shed 2000–10,000 individual 
platelets, which shows great clinical significance. Most 
observers pay much attention to the mechanisms active 
in the cytoskeleton of proplatelets and platelets (Hartwig 
and Italiano 2006; Thon et al. 2010). The current model 
of platelet formation recognizes that mature megakaryo-
cytes extend long, branching processes, called proplate-
lets, which are composed of platelet-sized swellings in 
tandem arrays that are connected by thin cytoplasmic 
bridges (Italiano et al. 1999). Proplatelets have been iden-
tified both in vitro and in vivo (Leven 1987; Tablin et al. 
1990), and proplatelet-producing megakaryocytes yield 
platelets that are parallel to blood platelets in structure 
and function (Behnke 1969; Choi et al. 1995). Neverthe-
less, the final stages of proplatelet maturation and plate-
let release remain little understood. Recently, Jonathan 
N. Thon and his colleagues identified a new intermedi-
ate stage in platelet production with enriched proplate-
let populations characterized for presence/absence of a 
nucleus, morphology, and size after double staining for 
nuclei and microtubules, termed preplatelets. According 
to their survey, preplatelets are anucleate discoid parti-
cles dramatically larger (2–10  μm) than blood platelets 
and have the ability to reversibly convert into proplatelets 
during cell culture (Thon et al. 2010).
Platelet production begins with the erosion of one pole 
of the megakaryocyte to generate large pseudopodial-like 
structures that elongate, thin, and branch to yield slen-
der tubular projections of uniform diameter (2–4  μm). 
Tablin and Leven first gained insight into the mechan-
ics of platelet formation, showing proplatelet elongation 
to be dependent on microtubules using specific poisons 
of microtubule assembly (Tablin et  al. 1990). We have 
learned that platelets mature only at the ends of highly 
branched proplatelets, and individual organelles are sent 
from the megakaryocyte cell body to the proplatelet 
where they move bidirectionally until they are captured 
at the proplatelet ends (Richardson et al. 2005). The slid-
ing movement of thick bundles of microtubules contrib-
utes to proplatelet formation, and by passing one another 
within the proplatelet shafts it is the primary motor for 
proplatelet elongation. The slide rate is expected to be 
4–5  μm/min within the proplatelets; the underlying 
mechanism remains unclear (Hartwig and Italiano 2006). 
Continued bidirectional polymerization of microtubules 
at each end of the barbell proplatelet forms two well-
defined platelet-sized microtubule loops at each end, and 
two individual platelets remain after a fission event.
Underlying details of how mature platelets release from 
the proplatelet tips are still elusive. The product released 
by megakaryocytes may be proplatelets, and the product 
released by proplatelets may be preplatelets and/or plate-
lets of various sizes. Whether the microtubule motors 
contribute to platelet release is unknown, but the fact 
that the dumbbell-shaped particles are easily released 
into the bathing media of megakaryocyte cultures may 
suggest that they are a preferred release form (Fig. 1).
Flow shear force
Recent work shows that when mature human MKs 
are exposed to high shear forces proplatelet processes 
become apparent and platelets are released within 
20  min. However, when left in static cultures often no 
platelets are generated or it takes several hours for plate-
lets to be released (Dunois-Lardé et  al. 2009). Shear 
enhances platelet release from proplatelet tips in marrow 
sinusoids in  vivo on the basis of intravital microscopic 
studies of mice (Junt et al. 2007). Whether the flow shear 
stress is the only mechanical force to sever platelets from 
proplatelet/preplatelet processes requires an intricate 
series of experiments to research, but the static nature 
of the majority of current culture protocols leads to low 
yields of platelets from culture-derived MKs. Studies of 
thrombopoiesis in lungs are consistent with shear force’s 
function in platelet release (Kaufman et  al. 1965; Schw-
ertz and Weyrich 2010). Many studies indicate that the 
lung is a site of platelet biogenesis, and in  vitro mod-
eling demonstrates that central events in thrombopoie-
sis are directed by cell-autonomous mechanisms and do 
not require the specific BM environment (Italiano et  al. 
2007). Proplatelet numbers were higher in prepulmonary 
blood than on the systemic side of lungs in rats, whereas 
platelets numbers were higher in systemic blood, which 
suggests that pulmonary vessels may be providing par-
ticularly favorable rheological conditions for the fission 
process (Kaufman et al. 1965; Handagama et al. 1987).
In summary, the HSC circulation involves mobiliza-
tion, HSCs leaving the BM, entering the vascular system, 
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and homing, i.e., returning to the BM. The main process 
of thrombopoiesis consists of: megakaryocyte precursor 
development from stem cell and cell fate determination; 
endomitosis and the development of polyploidy; internal 
membrane, tubular, cytoskeletal, and granule evolution 
directed by key transcription factors and transcription 
programs; regulated apoptosis (Weyrich and Zimmer-
man 2013); proplatelet formation; final platelet release by 
flow shear forces and other mechanisms; other intricate 
processes, etc. Nevertheless, little is known about physi-
ological megakaryopoiesis and thrombopoiesis processes 
to date, and further knowledge is needed urgently.
Platelet generation in vitro
Since the first report by Choi et  al. (1995) that human 
megakaryocytes and platelets could be generated in vitro 
from CD34+ peripheral blood progenitor cell, multi-
ple researchers also have proved that the generation of 
Fig. 1 The process of megakaryocyte differentiation and platelet production from HSCs within the niches. There are at least two niches in the bone 
marrow (BM) identified for HSC hematopoiesis, including the osteoblastic niche and the vascular niche. The HSCs live next to the endosteal bone 
surface, lined mainly by osteoblasts, which constitute the physiological microenvironment called the osteoblastic niche, providing a quiescent envi-
ronment for HSC maintenance. The vascular niche consists of HSCs and endothelial cells, offers an alternative niche for mobilized stem cells, and 
promotes proliferation and further differentiation or maturation into the circulation system. There may be four primarily sequential biological stages 
for thrombopoiesis and megakaryopoiesis. The self-renewal of HSCs living in the BM osteoblastic niches is the first step. Stem cells then proliferate 
and differentiate to increase the number of MK progenitors. In the third step of maturation events, MK progenitors undergo a process known as 
endomitosis. The fourth stage is characterized by platelet assembly and release. The current model of platelet formation recognizes that mature 
megakaryocytes extend long, branching processes, called proplatelets, which are composed of platelet-sized swellings in tandem arrays that are 
connected by thin cytoplasmic bridges. Platelet production begins with the erosion of one pole of the megakaryocyte to generate large pseudopo-
dial-like structures that elongate, thin, and branch to yield slender tubular projections of uniform diameter (2–4 μm). The product released by mega-
karyocytes may be proplatelets, and the product released by proplatelets may be preplatelets and/or platelets of various sizes. The red dotted line 
showed HSC circulation, which contains HSCs leaving the BM, entering the vascular system (termed mobilization), and returning to the BM (known 
as homing). However, the underlying physiological function of these events remains elusive. SNO cell spindle-shaped N-cadheri+CD45− osteoblastic 
cell, MEP megakaryocyte-erythroid progenitor, HSCs hematopoietic stem cells, MK megakaryocyte
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megakaryocytes and platelets could start with CD34+ 
progenitor cells derived either from umbilical cord blood 
(Tao et  al. 1999), fetal liver (Ma et  al. 2000), peripheral 
blood (Bruyn et  al. 2005), human embryonic stem cells 
(hESCs) (Gaur et al. 2006; Takayama et al. 2008), human 
induced pluripotent stem cells (hiPSCs) (Gekas and Graf 
2010; Takahashi et al. 2007), or bone marrow (Guerriero 
et al. 1995). Multiple culture systems appear, though each 
system has its own different limitation for large scale 
of regeneration of megakaryocytes and platelets. Most 
of these progenitor cell sources still require a continu-
ous supply of donors due to limited expansion potential, 
however, iPSCs and hESCs show great capacity to serve 
as renewable and unlimited sources of cells that can be 
expanded in culture and differentiated into megakaryo-
cytes (Lambert et al. 2013). Nevertheless, there remains 
a concern that any cellular product derived from pluri-
potent ESCs or iPSCs could be oncogenic or teratogenic 
(Ben-David and Benvenisty 2011). Recently, Wang et  al. 
(2012) first produced functional platelets using human 
endometrial stromal stem cells (hESSCs) in a serum-free 
medium supplemented with TPO in an in  vitro culture 
system. However, there is still no one universally accepted 
perfect stem cell source for in vitro MK/PLT production.
Human induced pluripotent stem cells (iPSCs)
Kazutoshi Takahashi and Shinya Yamanaka first gener-
ated induced pluripotent stem cells (iPSCs) directly from 
a mouse embryonic or adult fibroblast culture by intro-
ducing four essential transcription factors: Oct3/4, Sox2, 
c-Myc, and Klf4 (Takahashi and Yamanaka 2006). In this 
study, their operation of subcutaneous injection of iPSCs 
into nude mice, resulting in tumors containing varie-
ties of tissue from all three germ layers (Takahashi and 
Yamanaka 2006), which shows the promising capacity of 
iPSCs in differentiation. Subsequently, Takayama et  al. 
(2010) successfully produced platelets from individual 
four-factor hiPSC clones established from human dermal 
fibroblasts (HDFs)These human iPSC-derived platelets 
show satisfactory functionality in vitro and in vivo in the 
NOG (nod-scid/IL-2 γc-null) mouse thrombocytopenia 
model; however, large scale platelet production is little 
mentioned in this article. In addition, they also provide 
insight into the role of c-Myc in megakaryopoiesis and 
thrombopoiesis (Takayama et al. 2010). The assumption 
that c-Myc has both positive and negative targets that 
influence megakaryopoiesis and that these targets are 
regulated in a manner sensitive to different transcrip-
tion factor concentrations is accepted now Gekas and 
Graf (2010). Similarly, Nishimura et al. (2013) generated 
for the first time MKs and functional platelets in  vitro 
using canine induced pluripotent stem cells (ciPSCs) 
with the 29  % ratio of peripheral platelets positive for 
CD41/61 Abs and 17 % of platelets from culture superna-
tant (Nishimura et al. 2013), which shows the possibility 
of MK generation and the release of functional platelets 
from iPSCs.
Little research about large-scale megakaryopoiesis and 
thrombopoiesis from iPSCs was reported until recent 
years. In the US, Feng et  al. (2014) generated universal 
platelets from hiPSCs in the absence of serum and animal 
feeders, which is a simplified culture system following the 
EASHF rules, in less than 20  days. In total they gener-
ated 2.06 × 109 megakaryocyte progenitors (MKPs) from 
1.26 × 108 iPSCs, an average of >16 MKPs per single iPSC 
input. Significantly, they deleted the β2-microglobulin 
gene, generating “universal platelets” that are negative for 
major histocompatibility antigens (Feng et al. 2014). They 
also demonstrated that approximately 30 platelets per 
iPSC MK could be generated in vitro in the presence of 
shear force not too long ago (Thon et al. 2014); however, 
efficiency is currently still low compared to >2000 plate-
lets/MK in BM. Recently, Nakamura et al. (2014) sought 
to establish stable immortalized megakaryocyte progeni-
tor cell lines (imMKCLs) for clinically applicable genera-
tion of platelets from iPSCs. However, the technology of 
manufacturing functional platelets ex vivo from iPSCs is 
a relatively sophisticated reprogramming method. Thus, 
the challenge for reaching industrial scale generation of 
ex vivo platelets is still present. We propose that simpler 
culture systems and less strict experiment protocols for 
platelets generation from iPSCs are needed to take the 
next step forward.
Adipose‑derived stem cell (ADSC)
Compared with reprogrammed iPSCs, the advantage 
of using subcutaneous adipose tissues for platelet pro-
duction is obvious, since subcutaneous adipose tissues 
are easily obtained and available in quantity. Japanese 
researchers Yumiko Matsubara et  al. (2009) generated 
megakaryocyte and functional platelets from subcutane-
ous adipocyte precursor cells in an in  vitro culture sys-
tem for the first time in 2009.
Briefly, they used a two-step procedure in their plate-
let generation experiment. First they cultured primary 
human adipocyte precursors using Preadipocyte Growth 
Medium-2 BulletKit™ Medium, designated “mature adi-
pocyte media,” for differentiation into mature adipo-
cytes over 12 days. By day 12, approximately 80 % of cells 
showed differentiation into mature adipocytes. Secondly, 
cells were cultured in conditioned media in the pres-
ence of thrombopoietin (TPO), designated “TPO media,” 
to further differentiate into MK lineages for another 
12 days. As a result, approximately 2 × 106 ± 2500 and 
15  ×  104  ±  270 of MKs and platelets were produced, 
respectively. The DNA ploidy of the adipocyte precursor 
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cell-derived MKs reached 16 N (Matsubara et al. 2009). 
As stated previously, platelet production in  vivo is a 
highly efficient process, with 2000–10,000 platelets 
being produced from each MK precursors cell (Kaufman 
et al. 1965; Long 1998). However, many aspects remains 
imperfect in the experiment, such as the failure to iden-
tify the cell population that is responsible for generation 
of MKs and platelets, though the authors conjecture that 
the cell population differentiated into mature adipocytes 
may be responsible for megakaryopoiesis and throm-
bopoiesis. They state their assumption that mature adi-
pocytes have the ability to differentiate into MKs and 
platelets, but have no experiments proving it. As for the 
functional assay of adipocyte precursor cultured cell-
derived MKs/PLTs, they performed it only ex vivo; per-
formance in vivo is blank. Regardless, they have opened 
promising prospects for platelet generation ex  vivo in 
large quantities, since subcutaneous adipose tissue is 
easily obtained and available in large quantities (Matsub-
ara et al. 2012) and provides an abundant and accessible 
source of preadipocytes for regeneration medicine.
Additionally, the mouse bone marrow stroma cell line 
OP9 is regarded as pre-adipocyte and has been utilized as 
feeder cells for the differentiation of stem cells into MK 
lineages. Matsubara et  al. successfully generated func-
tional MKs and PLTs from OP9 cells using MK lineage 
induction medium. Moreover, they took a further step 
forward to explore the mechanism of MK differentia-
tion from pre-adipocyte OP9 cells. They revealed that the 
process of MK differentiation from OP9 cells had much 
to do with the gene expressions of p45NF-E2, FOG, Fli1, 
GATA2, RUNX1, TPO, and c-MPL, which regulates 
megakaryopoiesis and thrombopoiesis. Among them, 
the p45NF-E2 expression they observed was increased 
most markedly during the differentiation of OP9 cells 
into MK lineages. They further studied the effect of OP9 
cells transfected with p45NF-E2 on MK and PLT pro-
duction and found that the gene p45NF-E2 significantly 
elevated 1 × 106 OP9 cells, derived MKs production from 
(2.2 ± 1.6) × 104 for 1 × 106 empty-vector-OP9 cells to 
(3.3 ±  1.8) ×  104 for p45NF-E2-OP9 cells, respectively, 
and the number of platelets generated from 1 × 106 OP9 
cells was (2.9 ± 2.6) × 105 for the p45NF-E2-OP9-derived 
platelets and (1.0 ± 7.3) × 105 for the empty-vector-OP9-
derived platelets, which indicated that p45NF-E2 has 
a vital role in the generation of MKs and platelets from 
OP9 cells, the pre-adipocytes (Matsubara et al. 2013).
Human embryonic stem cells (hESCs)
Eto et al. (2002) successfully generated large, polyploidy 
MKs that produced proplatelets cocultured with OP9 
stromal cells in the presence of thrombopoietin, IL-6, 
and IL-11. In their system, IL-6 and IL-11 marginally 
enhanced the yield of viable, mature MKs, although they 
are not necessary for megakaryocytopoiesis. Typically, an 
initial culture of 1 ×  104 ES cells yields 6 ×  104 viable, 
αIIb-positive cells on day 12, of which two-thirds were 
large MKs. However, only 10  % of large MKs derived 
from ES cells were able to convert into proplatelets. Their 
study indirectly demonstrates that the efficient OP9 cul-
ture system can yield MKs on a sufficient scale and also 
indicates that MKs can be derived relatively rapidly and 
in quantity from ES cells. Eto et  al. (2003) introduced 
detailed methods for generating megakaryocytes in 
quantity from murine ES cells. Similarly, other research-
ers Kitajima et al. (2003), Fujimoto et al. (2003), Vodyanik 
et al. (2005), Gaur et al. (2006) also successfully induced 
differentiation of human/murine ES cells into MKs uti-
lizing the OP9 system, which convincingly demonstrates 
the abilities of the OP9 system in culturing MKs derived 
from ES cells. Further, Takayama et al. (2008) first found 
that vascular endothelial growth factor could promote 
the emergence of sac-like structures derived from embry-
onic stem cells (ES-sacs), which provided suitable con-
ditions for hematopoietic progenitors. Their results also 
showed that relatively large numbers of mature mega-
karyocytes could be induced from hematopoietic pro-
genitors within ES-sacs, which were then able to release 
functional platelets. And on average, (4.8  ±  0.2)  ×  106 
platelets were manufactured from initial 105 hESCs in the 
presence of a combination of TPO, stem cell factor (SCF), 
and heparin, which was considered the lower limit of the 
yield (Takayama et al. 2008).
However, the problem of how to generate functional 
megakaryocytes and platelets from hESCs on a large scale 
remains effectively unsolved. Recently, Lu et  al. (2011) 
took an important step toward generating an unlimited 
supply of platelets for transfusion. They first tried to uti-
lize an efficient method to generate functional MKs from 
hESCs on a large scale with hemangioblasts/blast cells 
(BCs) instead of OP9 cells as intermediates. Although 
they indeed harvested 6 × 108 CD41a+ MKs from about 
1.0 × 107 MA09 hESCs on a large scale as reported, on 
average only 6.7  ±  0.4 hESCs-PLTs were generated per 
hESCs-MK, the efficiency of which is still much lower 
than that observed in vivo as mentioned above. It is pos-
sible that the low efficiency is due to a shortage of nec-
essary shear force and other biological cytokines yet 
unknown. Absolutely the culture system needs to be 
improved further. Another inevitable obstacle to massive 
utilization of hESCs in clinical use lies in human ethic 
and moral principles.
Of course, many other different kinds of cell sources 
have been found and cultured to generate MKs/PLTs 
in  vitro, such as human embryonic stem cells (hESCs) 
(Olsen et al. 2006; Pick et al. 2013), hematopoietic stem 
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cells (HSCs) (Debili et  al. 1995; Mercher et  al. 2008), 
induced megakaryocytes (iMKs) (Masuda et  al. 2012), 
human CD34+ cells from bone marrow (BM), umbilical 
cord blood (CB) (Choi et al. 1995; Matsunaga et al. 2006), 
and even human endometrial stromal stem cells (hES-
SCs) (Wang et al. 2012). However, these cells cannot be 
utilized satisfactorily due to lack of resources and other 
reasons; therefore, it is not necessary to describe them 
in detail in the present article (Table  1). Exhilaratingly, 
Fuentes et al. (2010) offer an alternative approach to gen-
erating PLTs from megakaryocytes ex  vivo. They infuse 
mature MKs directly into mice and platelets are formed 
and released in vivo with characteristics similar to those 
of normal platelets. According to their estimation, 100–
200 platelets are generated per infused megakaryocyte 
(Fuentes et  al. 2010). This approach relies on research 
showing that megakaryocytes release platelets in the 
lungs (Zucker-Franklin and Philipp 2000). Other reports 
(Kaufman et al. 1965; Lu et al. 2011) are consistent with 
these findings, including an Andrew S. Weyrich review of 
platelet physiological function in the lung (Kaufman et al. 
1965; Weyrich and Zimmerman 2013) in 2013.
All these cells have already proven capable of differen-
tiating into megakaryocytes and platelets; however, for 
various reasons none is generally considered perfect or 
optimal for platelet generation on a large scale in vitro.
Conclusion
In summary, to alleviate the platelet transfusion stress 
discussed above, researchers around the world have 
sought to generate platelets mainly in two directions. 
One direction is that platelets are generated in vitro from 
various cell sources, such as HSCs, ADSC, CB, hESCs, 
etc. The other direction is that mature megakaryocytes 
are generated ex vivo and then infused into experimen-
tal objects, based on the theory of megakaryocytes shed-
ding platelets in lungs. In both directions one encounters 
many barriers. For instance, all ESCs and iPSCs are 
inherently tumorigenic and form teratomas in  vivo, but 
differentiated platelet cultures for cell replacement ther-
apy must be completely pure platelets without residual 
pluripotent cells. A generally accepted method for elimi-
nation of pluripotent cells is cell irradiation; however, 
as yet we have no idea whether the experimental object 
will have any adverse reactions when infused with large 
quantities of dead pluripotent cells fragments. BM and 
CB are donor dependent and the expansion capability 
of these cells is limited, and so on. The half-life of these 
platelets derived from infused MKs is slighter shorter 
than that of infused platelets, for reasons still unclear. In 
our opinion, ADSCs may play a starring role in industrial 
platelet generation due to abundant sources and differen-
tiation potency. In addition, we propose that the perfect 
culture system to manufacture platelets in  vitro should 
follow EASHF rules, including the easiest operation sys-
tem, most abundant precursor cell source, shortest cul-
ture period, highest yield efficiency, and fully functional 
platelets. We believe that the dream of platelet genera-
tion in vitro on an industrial scale will come true 1 day by 
means of a multidisciplinary combination, like Biomate-
rials Science, Mechanical Physics, etc.
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